NCT03095209View on ClinicalTrials.gov

Observation Study of Patients With Non-Small Cell Lung Cancer and Esophageal Cancer Treated With Chemo-Radiation Followed by Surgery

CompletedOBSERVATIONAL
Enrollment

6

Participants

Timeline

Start Date

February 24, 2017

Primary Completion Date

November 20, 2019

Study Completion Date

January 18, 2021

Conditions
Lung CancerEsophageal Cancer
Interventions
DRUG

Carboplatin

chemo regimen will carboplatin-paclitaxel managed by the treating medical oncologist. Patients are planned to receive surgery at approximately 6 to 9 weeks (maximum 12 weeks post-CRT) after finishing CRT with surgical aspects determined by the treating surgical oncologist.

DRUG

Paclitaxel

chemo regimen will carboplatin-paclitaxel managed by the treating medical oncologist. Patients are planned to receive surgery at approximately 6 to 9 weeks (maximum 12 weeks post-CRT) after finishing CRT with surgical aspects determined by the treating surgical oncologist.

RADIATION

Radiation Therapy

The total radiation dose will be 50.4 Gy in daily fraction of 1.8 Gy for esophageal cancer and 60 Gy in daily fraction of 2 Gy for non-small cell lung cancer.

Trial Locations (1)

19111

Fox Chase Cancer Center, Philadelphia

All Listed Sponsors
lead

Fox Chase Cancer Center

OTHER

NCT03095209 - Observation Study of Patients With Non-Small Cell Lung Cancer and Esophageal Cancer Treated With Chemo-Radiation Followed by Surgery | Biotech Hunter | Biotech Hunter